Catal­ent inks deal with Phath­om to make GI drug at re­cent­ly-ren­o­vat­ed Ken­tucky site

Sum­mer’s over, but New Jer­sey-based CD­MO Catal­ent had time to squeak in one last deal.

Catal­ent has signed an agree­ment to com­mer­cial­ly man­u­fac­ture Phath­om Phar­ma­ceu­ti­cals’ lead drug, vono­prazan, for the treat­ment of gas­troin­testi­nal dis­eases. If the drug is ap­proved by the FDA, Catal­ent will man­u­fac­ture and pack­age the drug at its large-scale oral sol­id dose site in Win­ches­ter, KY. Phath­om has the rights to de­vel­op and com­mer­cial­ize vono­prazan in the US, Eu­rope and Cana­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER